{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:43:24Z","timestamp":1794530604122,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7830","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2020,10,22]]},"DOI":"10.1038\/s41586-020-2814-7","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T06:05:26Z","timestamp":1601445926000},"page":"594-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1832,"title":["COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses"],"prefix":"10.1038","volume":"586","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0363-1564","authenticated-orcid":false,"given":"Ugur","family":"Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-2273","authenticated-orcid":false,"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyna","family":"Derhovanessian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9757-9618","authenticated-orcid":false,"given":"Isabel","family":"Vogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-3380","authenticated-orcid":false,"given":"Mathias","family":"Vormehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4826-4606","authenticated-orcid":false,"given":"Kristen","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-9941","authenticated-orcid":false,"given":"Jasmin","family":"Quandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Maurus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Brachtendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"L\u00f6rks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Sikorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-7731","authenticated-orcid":false,"given":"Rolf","family":"Hilker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Gr\u00fctzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Boesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Cristine","family":"K\u00fchnle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Luxemburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kemmer-Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-4343","authenticated-orcid":false,"given":"Martin","family":"Bexon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Bolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1864-3851","authenticated-orcid":false,"given":"Katalin","family":"Karik\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Palanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-1616","authenticated-orcid":false,"given":"Pei-Yong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Fontes-Garfias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-8414","authenticated-orcid":false,"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Loschko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid L.","family":"Scully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Kalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos A.","family":"Kyratsous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Dormitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"T\u00fcreci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"2814_CR1","doi-asserted-by":"publisher","unstructured":"Mulligan, M. J. et al. Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature https:\/\/doi.org\/10.1038\/s41586-020-2639-4 (2020).","DOI":"10.1038\/s41586-020-2639-4"},{"key":"2814_CR2","unstructured":"WHO. Coronavirus Disease (COVID-19) Dashboard (accessed 17 September 2020); https:\/\/covid19.who.int\/"},{"key":"2814_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15171\/ijoem.2020.1921","volume":"11","author":"P Habibzadeh","year":"2020","unstructured":"Habibzadeh, P. & Stoneman, E. K. The novel coronavirus: a bird\u2019s eye view. Int. J. Occup. Environ. Med. 11, 65\u201371 (2020).","journal-title":"Int. J. Occup. Environ. Med."},{"key":"2814_CR4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","volume":"215","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215, 1571\u20131588 (2018).","journal-title":"J. Exp. Med."},{"key":"2814_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6. mRNA-based therapeutics\u2014developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2814_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248\u2013251 (2017).","journal-title":"Nature"},{"key":"2814_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","volume":"15","author":"N Pardi","year":"2019","unstructured":"Pardi, N. et al. Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques. Mol. Ther. Nucleic Acids 15, 36\u201347 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2814_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112 (2020).","journal-title":"Nature"},{"key":"2814_CR9","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","volume":"9","author":"S Rauch","year":"2018","unstructured":"Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. Front. Immunol. 9, 1963 (2018).","journal-title":"Front. Immunol."},{"key":"2814_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217, 345\u2013351 (2015).","journal-title":"J. Control. Release"},{"key":"2814_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361 (2018).","journal-title":"Nat. Commun."},{"key":"2814_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","volume":"499","author":"W Tai","year":"2016","unstructured":"Tai, W. et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499, 375\u2013382 (2016).","journal-title":"Virology"},{"key":"2814_CR13","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","volume":"108","author":"S Holtkamp","year":"2006","unstructured":"Holtkamp, S. et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108, 4009\u20134017 (2006).","journal-title":"Blood"},{"key":"2814_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG Orlandini von Niessen","year":"2019","unstructured":"Orlandini von Niessen, A. G. et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2032 UTRs identified by cellular library screening. Mol. Ther. 27, 824\u2013836 (2019).","journal-title":"Mol. Ther."},{"key":"2814_CR15","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"2814_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.lab.2005.03.009","volume":"145","author":"MY Tsai","year":"2005","unstructured":"Tsai, M. Y. et al. Effect of influenza vaccine on markers of inflammation and lipid profile. J. Lab. Clin. Med. 145, 323\u2013327 (2005).","journal-title":"J. Lab. Clin. Med."},{"key":"2814_CR17","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1016\/j.vaccine.2012.06.086","volume":"30","author":"DN Taylor","year":"2012","unstructured":"Taylor, D. N. et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30, 5761\u20135769 (2012).","journal-title":"Vaccine"},{"key":"2814_CR18","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.vaccine.2019.02.024","volume":"37","author":"F Doener","year":"2019","unstructured":"Doener, F. et al. RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial. Vaccine 37, 1819\u20131826 (2019).","journal-title":"Vaccine"},{"key":"2814_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.vascn.2013.04.003","volume":"68","author":"E Destexhe","year":"2013","unstructured":"Destexhe, E. et al. Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies. J. Pharmacol. Toxicol. Methods 68, 367\u2013373 (2013).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2814_CR20","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2006-06-027599","volume":"108","author":"E Kamphuis","year":"2006","unstructured":"Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108, 3253\u20133261 (2006).","journal-title":"Blood"},{"key":"2814_CR21","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014\u20131018 (2020).","journal-title":"Science"},{"key":"2814_CR22","doi-asserted-by":"crossref","unstructured":"Zhang, L. et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.06.12.148726v1 (2020).","DOI":"10.1101\/2020.06.12.148726"},{"key":"2814_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.immuni.2008.04.018","volume":"28","author":"A Sette","year":"2008","unstructured":"Sette, A. et al. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28, 847\u2013858 (2008).","journal-title":"Immunity"},{"key":"2814_CR24","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","volume":"52","author":"N Vabret","year":"2020","unstructured":"Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity 52, 910\u2013941 (2020).","journal-title":"Immunity"},{"key":"2814_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.virol.2004.08.011","volume":"329","author":"B Sainz Jr","year":"2004","unstructured":"Sainz, B., Jr, Mossel, E. C., Peters, C. J. & Garry, R. F. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329, 11\u201317 (2004).","journal-title":"Virology"},{"key":"2814_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-82","volume":"6","author":"WP Chong","year":"2006","unstructured":"Chong, W. P. et al. The interferon gamma gene polymorphism +874 A\/T is associated with severe acute respiratory syndrome. BMC Infect. Dis. 6, 82 (2006).","journal-title":"BMC Infect. Dis."},{"key":"2814_CR27","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.vaccine.2016.02.063","volume":"34","author":"O-W Ng","year":"2016","unstructured":"Ng, O.-W. et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine 34, 2008\u20132014 (2016).","journal-title":"Vaccine"},{"key":"2814_CR28","doi-asserted-by":"crossref","unstructured":"Gallais, F. et al. Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.21.20132449v1 (2020).","DOI":"10.1101\/2020.06.21.20132449"},{"key":"2814_CR29","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650\u2013655 (2020).","journal-title":"Science"},{"key":"2814_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"2814_CR31","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37, 3326\u20133334 (2019).","journal-title":"Vaccine"},{"key":"2814_CR32","doi-asserted-by":"crossref","unstructured":"Walsh, E. E. et al. RNA-Based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.08.17.20176651v2 (2020).","DOI":"10.1101\/2020.08.17.20176651"},{"key":"2814_CR33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848.e3 (2020).","journal-title":"Cell Host Microbe"},{"key":"2814_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17892-0","volume":"11","author":"AE Muruato","year":"2020","unstructured":"Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 11, 4059 (2020).","journal-title":"Nat. Commun."},{"key":"2814_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jim.2006.07.015","volume":"315","author":"Z Moodie","year":"2006","unstructured":"Moodie, Z., Huang, Y., Gu, L., Hural, J. & Self, S. G. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J. Immunol. Methods 315, 121\u2013132 (2006).","journal-title":"J. Immunol. Methods"},{"key":"2814_CR36","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","volume":"59","author":"Z Moodie","year":"2010","unstructured":"Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489\u20131501 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"2814_CR37","unstructured":"U.S. Department of Health and Human Services. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical (2007)."}],"updated-by":[{"DOI":"10.1038\/s41586-020-03102-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2814-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T19:04:52Z","timestamp":1732820692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2814-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":37,"journal-issue":{"issue":"7830","published-print":{"date-parts":[[2020,10,22]]}},"alternative-id":["2814"],"URL":"https:\/\/doi.org\/10.1038\/s41586-020-2814-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738762663.793579438","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.17.20140533","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published: https:\/\/doi.org\/10.1038\/s41586-020-03102-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have completed the International Committee of Medical Journal Editors (ICMJE) uniform disclosure form at https:\/\/www.gisaid.orgwww.icmje.org\/coi_disclosure.pdf` and declare: U.S. and \u00d6.T. are management board members and employees at BioNTech SE (Mainz, Germany); D.B., C.B., S. Brachtendorf, E.D., A.-K.E., B.F., J.G., R.H., M.-C.K., U.L., V.L., D.M., C.R., J.S. and T.P. are employees at BioNTech SE; K.K., L.M.K., I.V., A.M., J.Q. and M.V. are employees at BioNTech RNA Pharmaceuticals GmbH; M.B. is an employee at Bexon Clinical Consulting LLC. A.B., C.A.K. and K.P. are employees of Regeneron Pharmaceuticals Inc; K.K., A.M., U.S. and \u00d6.T. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccine; D.B., C.B., S. Bolte, E.D., J.G., K.K., R.H., A.K.-B., L.M.K., D.L., U.L., A.M., C.R., U.S., \u00d6.T., I.V. and M.V. have securities from BioNTech SE; D.C., M.C., P.R.D., K.U.J., W.K., J.L., J.L.P., I.L.S. and K.A.S. are employees at Pfizer and may have securities from Pfizer; C.A.K. is an officer at Regeneron Pharmaceuticals, Inc; A.B., C.A.K. and K.P. have securities from Regeneron Pharmaceuticals, Inc; C.F.-G. and P.-Y.S. received compensation from Pfizer to perform the neutralization assay; no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}